Home / Centerstage / 2015 / March / Week 1 /
The U.S. Food and Drug Administration (FDA) grants approval for Zarxio, the country's first biosimilar drug, developed by Novartis. Biosimilars are cost-effective alternatives to complex biologic drugs, with Zarxio being a close copy of Neupogen. This milestone approval paves the way for increased accessibility and affordability of biologic therapies, benefiting patients undergoing chemotherapy and opening avenues for future biosimilar developments.
Thursday, 5 March, 2015